In this episode of "The Top Line," Annalee Armstrong and Gabrielle Masson shine a spotlight on some of the most promising companies in the biotech world.
Additionally, you'll have the opportunity to hear from Kevin Dunleavy as he engages in a conversation with Ray Pressburger from Accenture, discussing drug commercialization and the models that are proving to be the most effective.
To learn more about the topics in this episode:
- Introducing Fierce Biotech's 2023 Fierce 15
- Commercial innovation is key to maximizing sales, as traditional approaches underperform: Accenture report
- Pharma can no longer rely on traditional sales and marketing to launch new drugs: report
- 'It's going to get worse': Providers tap into health tech tools to prevent maternal health emergencies
- Fierce Biotech Fundraising Tracker '23: Hyku hatches with $56M seed; Magnet makes money moves with $50M emergence